Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Does the type of hand sanitizer matter? A study involving 568 people suggests it might (opens in a new tab)

news-medical.net · 2026-10-14

Short answerEvidenceSource

Short answer

Mixed

Mixed.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

  • 3 supported
  • 3 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

Every claim we could check holds up. Three of six claims match the study. This overall rating is based only on the claims we could check. Three claims the study doesn't address.

  • 3 supported
  • 3 not covered
Open claim evidence
3

The source study

Effects of a hand sanitizer formulation on upper respiratory symptoms and work restrictions: a double-blind household cluster-randomized controlled trial

Scientific Reports · 2026
Open source record (opens in a new tab)
Source paper

Source layer

The 2 papers the story cites

Source study separated from background citations.

The research anchor for the report.

  • The study this story reportsmentioned without context

    Effects of a hand sanitizer formulation on upper respiratory symptoms and work restrictions: a double-blind household cluster-randomized controlled trial

    Scientific Reports · 2026

    Publisher (opens in a new tab)
  • The study this story reportspresented as the new finding

    Effects of a hand sanitizer formulation on upper respiratory symptoms and work restrictions: a double-blind household cluster-randomized controlled trial

    Scientific Reports · 2026

    Publisher (opens in a new tab)
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

6 claims in this story

Showing all 6 claimsChoose a verdict to focus the list.

Claim 1 of 6Not coveredMost hand sanitizers offer little protection against recontamination between applications, so a winter trial in Japanese households tested whether a formulation designed to remain active on the skin could make a difference.View evidenceHide evidence

Why this verdict

The abstract-level profile supports the broad rationale that conventional hand sanitizers have short-lived bactericidal/virucidal effects and that a 72-day household cluster-randomized winter trial compared a study formulation with a 79.7% ethanol sanitizer. However, at abstract depth it does not verify several framed details: that the trial was specifically in Japan, that the formulation was designed to remain active on skin, or that recontamination between applications was the directly stated problem.

1

Study evidence

Repeated use of the study hand-sanitizer formulation was associated with a lower hazard of upper respiratory symptoms compared with the 79.7% ethanol-based sanitizer.HR 0.58 (95% CI 0.37–0.89), P = 0.013

“This double-blind, parallel-group, cluster-randomized controlled trial evaluated the effect of repeated use of the study formulation.”
Claim 2 of 6Not coveredIllness-related work restrictions lasting one or more days were reported to be 51% lower in the study formulation group, affecting 14.7% versus 23.7% in the commercial sanitizer group.View evidenceHide evidence

As stated51% lower; 14.7% vs 23.7%

Why this verdict

The abstract-level profile supports only the qualitative direction that the study-formulation group had fewer illness-related work restrictions. It explicitly notes that the abstract provides no numerical effect estimate, confidence interval, p-value, operational definition, or statistical detail for this endpoint, so the stated 51% lower figure, 14.7% versus 23.7%, and 'one or more days' threshold are not verifiable at this evidence depth.

1

Study evidence

The abstract reports that the study-formulation group experienced fewer illness-related work restrictions than the ethanol-based sanitizer group during the 72-day follow-up.

“The study-formulation group showed significantly lower risk ... with fewer illness-related work restrictions.”
Claim 3 of 6Not coveredThe article says the study formulation also showed reductions in sneezing and fatigue, while noting that residual antimicrobial activity remains a hypothetical mechanism because hand recontamination and residual activity were not directly measured.View evidenceHide evidence

As statedapproximately 62% and 54% lower hazards for sneezing and fatigue

Why this verdict

The abstract-level profile does not report sneezing or fatigue as separate outcomes, nor does it state that residual antimicrobial activity, hand recontamination, or the proposed mechanism were or were not directly measured. The general primary symptom result is supported, but the specific symptom reductions and mechanistic caveat are not verifiable from the supplied abstract-depth profile.

1

Study evidence

Repeated use of the study hand-sanitizer formulation was associated with a lower hazard of upper respiratory symptoms compared with the 79.7% ethanol-based sanitizer.HR 0.58 (95% CI 0.37–0.89), P = 0.013

“This double-blind, parallel-group, cluster-randomized controlled trial evaluated the effect of repeated use of the study formulation.”
Claim 4 of 6SupportedA recent study published in Scientific Reports found that repeated use of a custom formulation was associated with fewer upper respiratory symptoms and fewer illness-related work restrictions than a commercial ethanol-based sanitizer.View evidenceHide evidence

As statedfewer upper respiratory symptoms; fewer illness-related work restrictions

Why this verdict

The profile supports that the Scientific Reports study compared repeated use of the study formulation with a commercially available 79.7% ethanol-based sanitizer and found a lower hazard of upper respiratory symptoms plus fewer illness-related work restrictions in the study-formulation arm. The wording is appropriately associational/hedged.

1

Study evidence

Repeated use of the study hand-sanitizer formulation was associated with a lower hazard of upper respiratory symptoms compared with the 79.7% ethanol-based sanitizer.HR 0.58 (95% CI 0.37–0.89), P = 0.013

“This double-blind, parallel-group, cluster-randomized controlled trial evaluated the effect of repeated use of the study formulation.”
2

Study evidence

The abstract reports that the study-formulation group experienced fewer illness-related work restrictions than the ethanol-based sanitizer group during the 72-day follow-up.

“The study-formulation group showed significantly lower risk ... with fewer illness-related work restrictions.”
Claim 5 of 6SupportedThe investigators conducted a double-blinded household cluster-randomized controlled trial in 417 households with 568 participants, comparing a study formulation to a 79.7% ethanol sanitizer used 5-10 times per day for 72 days.View evidenceHide evidence

As stated568 participants; 417 households; 72 days

Why this verdict

The abstract-level profile states this was a double-blind, parallel-group household cluster-randomized controlled trial with 568 participants across 417 clusters, comparing the study formulation with a 79.7% ethanol-based sanitizer used 5–10 times daily for 72 days.

1

Study evidence

Repeated use of the study hand-sanitizer formulation was associated with a lower hazard of upper respiratory symptoms compared with the 79.7% ethanol-based sanitizer.HR 0.58 (95% CI 0.37–0.89), P = 0.013

“This double-blind, parallel-group, cluster-randomized controlled trial evaluated the effect of repeated use of the study formulation.”
Claim 6 of 6SupportedThe study formulation group had 35 people with upper respiratory symptoms versus 58 in the commercial sanitizer group, corresponding to an estimated 42% lower hazard and about 40% lower cumulative incidence.View evidenceHide evidence

As stated42% lower hazard; about 40% lower cumulative incidence

Why this verdict

The profile reports 35 primary-outcome events in the study-formulation group versus 58 in the ethanol group, HR 0.58, and describes this as approximately 40% lower cumulative incidence. Interpreting HR 0.58 as a 42% lower hazard is consistent with the reported estimate.

1

Study evidence

Repeated use of the study hand-sanitizer formulation was associated with a lower hazard of upper respiratory symptoms compared with the 79.7% ethanol-based sanitizer.HR 0.58 (95% CI 0.37–0.89), P = 0.013

“This double-blind, parallel-group, cluster-randomized controlled trial evaluated the effect of repeated use of the study formulation.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Primary outcome definition: cumulative incidence of upper respiratory symptoms defined as fever ≥37.8 °C with cough, sore throat, and/or nasal discharge.

    The story refers generally to 'upper respiratory symptoms' but does not reflect the paper profile’s narrower operational definition of the primary endpoint.

    From Double-blind household cluster-randomized parallel-group trial

  • Secondary work-restriction result: the abstract reports fewer illness-related work restrictions in the study-formulation group but does not provide numeric estimates, confidence intervals, p-values, or detailed methods for this endpoint.

    The story reflects the direction of the secondary finding, but it presents specific numerical estimates that are not available in the supplied abstract-depth profile and does not reflect the abstract-level limitation that the work-restriction endpoint lacks detailed reporting there.

    From Double-blind, parallel-group household cluster-randomized controlled trial

  • Work-restriction limitations: the abstract does not specify the operational definition, ascertainment method, adjudication, or analysis accounting for clustering for illness-related work restrictions; potential reporting or measurement bias cannot be assessed at abstract depth.

    The story’s caveats mention self-report and lack of laboratory confirmation for symptoms, but do not specifically acknowledge the supplied profile’s limitations for the work-restriction outcome.

    From Double-blind, parallel-group household cluster-randomized controlled trial

  • Safety/tolerability contribution: adverse events were reported as infrequent and unrelated to the interventions, and repeated use of the study formulation was described as well tolerated.

    The supplied paper profile treats safety/tolerability as a secondary contribution, but the story claims and caveats supplied here do not discuss the adverse-event finding.

    From Double-blind household cluster-randomized controlled trial; harms/adverse-event collection during randomized exposure wi

  • Safety-reporting limitations: at abstract depth there are no adverse-event counts or rates by arm, severity or seriousness details, timing, withdrawal information, or described causality/adjudication procedures.

    Because the story does not cover the adverse-event result, it also does not reflect the profile’s safety-reporting limitations.

    From Double-blind household cluster-randomized controlled trial; harms/adverse-event collection during randomized exposure wi

3 things the story did carry across
  • Core trial design: double-blind, parallel-group household cluster-randomized controlled trial comparing repeated use of the study formulation with a commercially available 79.7% ethanol-based sanitizer for 72 days.
  • Primary efficacy result: 35 versus 58 participants experienced the primary upper-respiratory-symptom outcome; HR 0.58, 95% CI 0.37–0.89, P=0.013, corresponding to about 40% lower cumulative incidence.
  • Comparator scope: the trial compared two active sanitizer regimens, study formulation versus 79.7% ethanol-based sanitizer, rather than measuring absolute protection against no sanitizer.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

3

Evidence read

study summary

Lead result

human in vivo

1Lead resulthuman in vivoDetermine whether repeated use of the study hand sanitizer formulation reduces upper respiratory symptoms compared with a commercially available 79.7% ethanol-based sanitizer in a double-blind household cluster-randomized trial.Double-blind household cluster-randomized parallel-group trialExpand

In plain English

Double-blind, parallel-group, household cluster-randomized trial (72 days) comparing repeated use (5–10×/day) of a study hand-sanitizer formulation versus a 79.7% ethanol-based sanitizer; primary outcome was cumulative incidence of upper respiratory symptoms (fever ≥ 37.8 °C with cough, sore throat, and/or nasal discharge). Among 568 participants (285 study-formulation; 283 ethanol) across 417 clusters, 35 vs 58 participants experienced the primary outcome; the study-formulation group had a lower hazard of symptoms (HR 0.58, 95% CI 0.37–0.89, P = 0.013). Fewer illness-related work restrictions and infrequent, intervention-unrelated adverse events were reported for the study formulation.

Key findings

  • Repeated use of the study hand-sanitizer formulation was associated with a lower hazard of upper respiratory symptoms compared with the 79.7% ethanol-based sanitizer.HR 0.58 (95% CI 0.37–0.89), P = 0.013
  • The study-formulation group experienced fewer illness-related work restrictions than the ethanol-based sanitizer group.
“This double-blind, parallel-group, cluster-randomized controlled trial evaluated the effect of repeated use of the study formulation.”
2human in vivoAssess whether the study formulation reduces illness-related work restrictions compared with the ethanol-based sanitizer.Double-blind, parallel-group household cluster-randomized controlled trialExpand

In plain English

In the double-blind, parallel-group household cluster-randomized trial described in the abstract (72-day follow-up; participants used assigned sanitizer 5–10 times daily), the authors report that the study formulation was associated with fewer illness-related work restrictions than a 79.7% ethanol-based sanitizer. This is presented as a secondary outcome in the abstract without numeric effect estimates or statistical detail for this endpoint.

Key findings

  • The abstract reports that the study-formulation group experienced fewer illness-related work restrictions than the ethanol-based sanitizer group during the 72-day follow-up.
“The study-formulation group showed significantly lower risk ... with fewer illness-related work restrictions.”
What this piece can’t prove
  • Potential measurement or reporting bias for secondary outcomes if based on participant report; abstract provides no adjudication details.
  • Generalisability limited to the trial population (healthy employees and cohabiting family members) and the 72-day winter follow-up period reported.

3 further details could not be confirmed from the summary.

3human in vivoEvaluate tolerability/safety (adverse events) of repeated use of the study formulation versus ethanol-based sanitizer over 72 days.Double-blind household cluster-randomized controlled trial; harms/adverse-event collection during randomized exposure windowExpand

In plain English

In a double-blind household cluster-randomized trial of 568 participants (285 assigned to the study formulation, 283 to a 79.7% ethanol sanitizer) conducted over 72 days, the abstract reports that adverse events were infrequent, judged unrelated to the interventions, and that repeated use of the study formulation was well tolerated. Safety was assessed over the same randomized exposure window in the trial cohort. The abstract provides no numerical adverse-event counts, definitions, severity grading, seriousness/SAE descriptions, or details on adverse-event ascertainment or attribution.

Key findings

  • Adverse events were infrequent and reported as unrelated to the study interventions; the study formulation was described as well tolerated with repeated use over 72 days.
“Adverse events were infrequent and unrelated to the study interventions.”
What this piece can’t prove
  • Lack of numerical AE data, severity/seriousness information, and methods for attribution limits interpretation of tolerability claims.
  • Unclear whether AE monitoring was active vs passive, who assessed causality, and whether any withdrawals occurred for safety reasons.

1 further detail could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Open the paper in Tessa

Effects of a hand sanitizer formulation on upper respiratory symptoms and work restrictions: a double-blind household cluster-randomized controlled trial

Scientific Reports · 2026

Source record (opens in a new tab)

Why this one

Near certain

NewsLink found the paper. Tessa is where you inspect it deeply.

Papers considered

The selected paper, plus nearby candidates.

Crossref, Europe PMC, PubMed · 39 candidate papers

Selected

Effects of a hand sanitizer formulation on upper respiratory symptoms and work restrictions: a double-blind household cluster-randomized controlled trial

Scientific Reports · 2026 · Crossref

Source (opens in a new tab)
Candidate

Author Correction: Inference limits in partially observable Ethereum blockchains

Scientific Reports · 2026 · Crossref

Source (opens in a new tab)

And 33 more candidates considered.